



PSORIASIS

## COMBINATION BIOLOGIC THERAPY: GUSELKUMAB PLUS ADALIMUMAB IN A PATIENT WITH PSORIATIC DISEASE

*M Goldust<sup>(1)</sup> - U Wollina<sup>(2)</sup> - Ps Yamauchi<sup>(3)</sup>*

*Mazandaran University Of Medical Sciences, Dermatology, Sari, Iran (islamic Republic Of)<sup>(1)</sup> - ,städtisches Klinikum Dresden, Academic Teaching Hospital Of The Technical University Of Dresden, Department Of Dermatology And Allergology, Dresden, Germany<sup>(2)</sup> - David Geffen School Of Medicine At University Of California, Division Of Dermatology, Los Angeles, United States<sup>(3)</sup>*

**Background:** The biological drugs used to treat psoriatic disease act by blocking the action of a specific type of immune cell or by blocking proteins in the immune system.

**Observation:** We present a 46-year-old woman with a 12-year history of severe plaque psoriasis and psoriatic arthritis who did not respond to several prior treatments including topical corticosteroids, narrow-band ultraviolet B phototherapy. This patient, receiving concomitant treatment with adalimumab and guselkumab, experienced a great reduction in both the signs and symptoms of psoriatic disease.

**Key message:** Although our patient who did not respond to multiple other approaches could experience dramatic improvement in disease control with combination biologic agents, it is not clear whether her improvement was due to combination therapy or treatment with new biologic agent like guselkumab which is able to achieve Psoriasis Area and Severity Index (PASI) 90 in most patients when administered as a monotherapy. Further studies need to be done in order to evaluate the efficacy and safety of biological agent's combination therapy.

